# MaaT Pharma

Source: https://onco.cc/companies/maat-pharma/  
OnCo record `maat-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MaaT Pharma makes gut microbiome treatments for people with blood cancer. Its lead product restores gut bacteria to treat a severe complication of stem cell transplants when standard drugs fail.

## Summary

MaaT Pharma (Euronext Paris: MAAT), founded in 2014 in Lyon, develops Microbiome Ecosystem Therapies supported by its gutPrint AI discovery engine and in-house cGMP manufacturing. Lead product Xervyteg (MaaT013), a pooled full-ecosystem microbiome therapy, is intended for steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation; more than 230 patients have been treated under early access across 13 countries. In June 2026 the EMA's CHMP issued a negative opinion and MaaT Pharma said it would request re-examination. MaaT033, an oral capsule, is in the PHOEBUS trial in allogeneic transplant recipients, described as potentially pivotal in Europe, with one-year overall survival data expected in late 2028. Cash was EUR 18.1 million at 31 March 2026; a EUR 6 million European Investment Bank loan tranche drawn in April 2026 extended runway to November 2026.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Lyon
- Type: biotech
- Website: https://www.maatpharma.com
- Ticker: MAAT.PA

## Sources

- Official website: https://www.maatpharma.com
- Q1 2026 business update: https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/
- Plan to request re-examination after negative CHMP opinion (June 2026): https://www.maatpharma.com/june-26-2026-maat-pharma-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-maat013-for-the-treatment-of-acute-graft-versus-host-disease/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- trials: [Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot](https://onco.cc/trials/nct07001618/)
- roadmaps: [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/maat-pharma.json